Literature DB >> 9736491

Liposome-anchored vascular endothelial growth factor aptamers.

M C Willis1, B D Collins, T Zhang, L S Green, D P Sebesta, C Bell, E Kellogg, S C Gill, A Magallanez, S Knauer, R A Bendele, P S Gill, N Janjić, B Collins.   

Abstract

Nuclease-resistant aptamers identified from randomized nucleic acid libraries represent a novel class of drug candidates. Aptamers are synthesized chemically and therefore can be readily modified with functional groups that modulate their properties. We report here on the preparation, initial characterization, and functional properties of a nuclease-resistant vascular endothelial growth factor (VEGF) aptamer anchored in liposome bilayers through a lipid group on the aptamer. While the high-affinity binding to VEGF is maintained, the plasma residence time of the liposome-anchored aptamer is considerably improved compared with that of the free aptamer. The lipid group attachment and/or liposome anchoring leads to a dramatic improvement in inhibitory activity of the aptamer toward VEGF-induced endothelial cell proliferation in vitro and vascular permeability increase and angiogenesis in vivo.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9736491     DOI: 10.1021/bc980002x

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  43 in total

1.  Developing aptamers into therapeutics.

Authors:  R R White; B A Sullenger; C P Rusconi
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

2.  Expanding the concept of chemically programmable antibodies to RNA aptamers: chemically programmed biotherapeutics.

Authors:  Ulrich Wuellner; Julia I Gavrilyuk; Carlos F Barbas
Journal:  Angew Chem Int Ed Engl       Date:  2010-08-09       Impact factor: 15.336

Review 3.  Molecular imaging with nanoparticles: giant roles for dwarf actors.

Authors:  Paul Debbage; Werner Jaschke
Journal:  Histochem Cell Biol       Date:  2008-09-30       Impact factor: 4.304

4.  Blocking the attachment of cancer cells in vivo with DNA aptamers displaying anti-adhesive properties against the carcinoembryonic antigen.

Authors:  Erik W Orava; Aws Abdul-Wahid; Eric H-B Huang; Amirul Islam Mallick; Jean Gariépy
Journal:  Mol Oncol       Date:  2013-04-11       Impact factor: 6.603

Review 5.  Molecular aptamers for drug delivery.

Authors:  Weihong Tan; Hui Wang; Yan Chen; Xiaobing Zhang; Haizhen Zhu; Chaoyong Yang; Ronghua Yang; Chen Liu
Journal:  Trends Biotechnol       Date:  2011-08-06       Impact factor: 19.536

6.  Aptamer-conjugated polymeric nanoparticles for targeted cancer therapy.

Authors:  Athulya Aravind; Yasuhiko Yoshida; Toru Maekawa; D Sakthi Kumar
Journal:  Drug Deliv Transl Res       Date:  2012-12       Impact factor: 4.617

Review 7.  Tumor vasculature directed drug targeting: applying new technologies and knowledge to the development of clinically relevant therapies.

Authors:  Grietje Molema
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

8.  Multi-gene targeted antiangiogenic therapies for experimental corneal neovascularization.

Authors:  Peng Chen; Hongmei Yin; Yao Wang; Jing Mi; Wenxiao He; Lixin Xie; Yiqiang Wang
Journal:  Mol Vis       Date:  2010-02-27       Impact factor: 2.367

9.  Development of the anti-VEGF aptamer to a therapeutic agent for clinical ophthalmology.

Authors:  Cleber A Trujillo; Arthur A Nery; Janaína M Alves; Antonio H Martins; Henning Ulrich
Journal:  Clin Ophthalmol       Date:  2007-12

10.  Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics.

Authors:  John S Vorhies; John J Nemunaitis
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.